ライフサイエンスコーパス: Fms-like tyrosine kinase

1 by two homologous tyrosine kinase receptors, fms-like tyrosine kinase 1 (Flt-1) and kinase domain rec

2 Furthermore, VEGF receptor fms-like tyrosine kinase 1 (Flt-1) was elevated, whereas

3 r endothelial growth factor and its receptor fms-like tyrosine kinase 1 (Flt1) were up-regulated, and

4 enhanced expression of PGF and its receptor, FMS-like tyrosine kinase 1 (Flt1).

5 GF-induced phosphorylation of KDR but not of FMS-like tyrosine kinase 1 (FLT1)/VEGF receptor 1.

6 Here we show that FMS-like tyrosine kinase 1 (Flt1, also known as VEGFR1)

7 e placental growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) as clinical biomarke

8 or limits angiogenesis by increasing soluble fms-like tyrosine kinase 1 (sFlt-1) gene expression.

9 Excess soluble fms-like tyrosine kinase 1 (sFlt-1) of vascular endothel

10 The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth

11 Soluble fms-like tyrosine kinase 1 (sFlt-1), an alternatively sp

12 s of placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), and soluble endogli

13 ns of VEGF and its soluble receptor, soluble fms-like tyrosine kinase 1 (sFlt-1), were measured by en

14 data suggest that excess circulating soluble fms-like tyrosine kinase 1 (sFlt-1), which binds placent

15 levels of other angiogenic proteins [soluble fms-like tyrosine kinase 1 (sFlt1) and placental growth

16 ured plasma levels of antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt1) and proangiogenic pla

17 Up-regulation of placental soluble fms-like tyrosine kinase 1 (sFlt1) contributes to the pa

18 Soluble fms-like tyrosine kinase 1 (sFlt1), a circulating antian

19 rictor sensitivity and elevations in soluble fms-like tyrosine kinase 1 (sFLT1), a circulating antian

20 g PM, placental trophoblasts produce soluble fms-like tyrosine kinase 1 (sFlt1), also known as solubl

21 Here, we confirm that placental soluble fms-like tyrosine kinase 1 (sFlt1), an antagonist of VEG

22 Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic pr

23 The angiogenic factors soluble fms-like tyrosine kinase 1 and placental growth factor,

24 uteroplacental tissues, and elevated soluble fms-like tyrosine kinase 1 and soluble endoglin, markers

25 giogenic ligand PlGF and its target receptor fms-like tyrosine kinase 1 modulate vascular growth and

26 The antepartum ratio of soluble fms-like tyrosine kinase 1 to placental growth factor po

27 t tertile of the antepartum ratio of soluble fms-like tyrosine kinase 1 to placental growth factor wa

28 ted blood pressure, increased plasma soluble fms-like tyrosine kinase 1, and renal dysfunction.

29 This locus is near the FLT1 gene encoding Fms-like tyrosine kinase 1, providing biological support

30 -scavenging soluble VEGF receptor 1 (soluble fms-like tyrosine kinase 1; sFlt-1).

31 Both LP plasma and soluble FMS-like tyrosine-kinase 1 (sFlt1) in NP plasma abolishe

32 dothelial growth factor (VEGF) receptor-1 or Fms-like tyrosine kinase-1 (Flt-1) but not VEGF receptor

33 receptors, fetal liver kinase-1 (flk-1) and fms-like tyrosine kinase-1 (flt-1), was examined in rat

34 nase (p85) is constitutively associated with FMS-like tyrosine kinase-1 (Flt-1).

35 s, placental-like growth factor, and soluble Fms-like tyrosine kinase-1 (sFlt-1) are associated with

36 inetics of the antiangiogenic factor soluble Fms-like tyrosine kinase-1 (sFlt-1) in 136 consecutive R

37 regulation of expression of VEGF or soluble fms-like tyrosine kinase-1 (sFlt-1) in both an aortic ri

38 with increased circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1) in the third trimest

39 Soluble Fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic

40 Soluble fms-like tyrosine kinase-1 (sFlt-1) seems to interfere w

41 lampsia is associated with increased soluble fms-like tyrosine kinase-1 (sFlt-1), a circulating antag

42 nta-derived growth factor (PLGF) and soluble Fms-like tyrosine kinase-1 (sFLT-1, the soluble form of

43 However, elevated levels of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta and i

44 rong evidence that overproduction of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta is a

45 giogenic factor and preeclampsia risk marker fms-like tyrosine kinase-1 (sFLT1) in the placenta tissu

46 ound, GYY4137, inhibited circulating soluble fms-like tyrosine kinase-1 and soluble endoglin levels a

47 rfering RNA increased the release of soluble fms-like tyrosine kinase-1 and soluble endoglin, as asse

48 nd hemin by abolishing both sEng and soluble fms-like tyrosine kinase-1 induction.

49 giogenesis by inducing both sEng and soluble fms-like tyrosine kinase-1 secretion from human villous

50 'FMS'-like tyrosine kinase 3 (FLT3) mutations in acute my

51 ophage colony stimulating factor I receptor (Fms)-like tyrosine kinase 3 (Flt-3) ligand supported fur

52 Mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most fre

53 Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute my

54 Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approxi

55 Constitutive activation of FMS-like tyrosine kinase 3 (FLT3) by internal tandem dup

56 Internal tandem duplication (ITD) of fms-like tyrosine kinase 3 (FLT3) in acute myeloid leuke

57 goal of this study was to define the role of FMS-like tyrosine kinase 3 (FLT3) in the heart.

58 nd the ensuing expansion of T(reg) cells are Fms-like tyrosine kinase 3 (Flt3) independent, occur in

59 Fms-like tyrosine kinase 3 (FLT3) inhibition has elicite

60 seen to emerge as resistant mutations after FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy.

61 teosome inhibitors, antiangiogenesis agents, Fms-like tyrosine kinase 3 (FLT3) inhibitors, and apopto

62 Oncogenic addiction to the Fms-like tyrosine kinase 3 (FLT3) is a hallmark of acute

63 FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine

64 Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine

65 Fms-like tyrosine kinase 3 (Flt3) is a type III receptor

66 FMS-like tyrosine kinase 3 (FLT3) is almost universally

67 FMS-like tyrosine kinase 3 (FLT3) is expressed in human

68 FMS-like tyrosine kinase 3 (FLT3) is mutated in approxim

69 Signal transduction of FMS-like tyrosine kinase 3 (FLT3) is regulated by protei

70 e myeloid leukemia (AML) and determined that FMS-like tyrosine kinase 3 (FLT3) is transactivated by S

71 xclusively from pre-DCs under the control of fms-like tyrosine kinase 3 (Flt3) ligand, inhibitor of D

72 Fms-like tyrosine kinase 3 (FLT3) mutations are associat

73 Ever since the recognition that FMS-like tyrosine kinase 3 (FLT3) mutations exert a prof

74 Activating FMS-like tyrosine kinase 3 (FLT3) mutations have been id

75 Constitutively activating mutations of FMS-like tyrosine kinase 3 (FLT3) occur in approximately

76 Mutations that activate the fms-like tyrosine kinase 3 (FLT3) receptor are among the

77 rnal tandem duplication (ITD) mutants of the Fms-like tyrosine kinase 3 (Flt3) receptor in leukemogen

78 Internal tandem duplications (ITDs) of the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kina

79 The fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kina

80 mia (AML) harbor activating mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kina

81 l-3-kinase (PI3K)/protein kinase B (AKT) and Fms-like tyrosine kinase 3 (FLT3) signaling are aberrant

82 on of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemi

83 Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain

84 FMS-like tyrosine kinase 3 (FLT3), a class III receptor

85 aled that normal villus epithelium expresses Fms-like tyrosine kinase 3 (Flt3), a known regulator of

86 ation and discovered that ADP transactivates Fms-like tyrosine kinase 3 (Flt3), a receptor tyrosine k

87 cation (ITD) in the juxtamembrane portion of Fms-like tyrosine kinase 3 (FLT3), a type III receptor t

88 The ligand for the receptor tyrosine kinase fms-like tyrosine kinase 3 (flt3), also referred to as f

89 r of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived grow

90 iated by HSC-specific genes such as CD34 and Fms-like tyrosine kinase 3 (FLT3), respectively.

91 Small molecule inhibitors that target fms-like tyrosine kinase 3 (FLT3)-activating mutations h

92 Multiple FMS-like tyrosine kinase 3 (FLT3)-inhibitors have been s

93 Signaling pathways regulated by mutant Fms-like tyrosine kinase 3 (FLT3)-internal tandem duplic

94 Rhesus macaques were injected with Fms-like tyrosine kinase 3 (Flt3)-ligand (FL) to expand

95 FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid l

96 tion was identified in the gene encoding the Fms-like tyrosine kinase 3 (Flt3).

97 A 46-year-old white woman with a history of Fms-like tyrosine kinase 3 acute myeloid leukemia presen

98 and primary patient specimens independent of Fms-like tyrosine kinase 3 expression and stromal-mediat

99 expansion, cooperated with mutations in the FMS-like tyrosine kinase 3 gene (Flt3(ITD)) and the nucl

100 An internal tandem duplication in the fms-like tyrosine kinase 3 gene (FLT3/ITD) is associated

101 is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhib

102 In Fms-like tyrosine kinase 3 internal tandem duplication (

103 In Fms-like tyrosine kinase 3 internal tandem duplication (

104 treated with the hematopoietic growth factor fms-like tyrosine kinase 3 ligand (FL), which dramatical

105 C precursors that can be expanded in vivo by Fms-like tyrosine kinase 3 ligand (FL).

106 Fms-like tyrosine kinase 3 ligand (Flt3L) administration

107 observation that Langerin-CD11b- migDCs are Fms-like tyrosine kinase 3 ligand (Flt3L) dependent and

108 Here, we observe subcutaneous immunity is Fms-like tyrosine kinase 3 ligand (Flt3L) dependent.

109 In contrast, injection of FMS-like tyrosine kinase 3 ligand (Flt3L) DNA, which exp

110 und that immunization of wild-type mice with FMS-like tyrosine kinase 3 ligand (Flt3L) DNA, which inc

111 Fms-like tyrosine kinase 3 ligand (Flt3L) expands dendri

112 Fms-like tyrosine kinase 3 ligand (Flt3L) is a hematopoi

113 ested this hypothesis by using DC-deficient, fms-like tyrosine kinase 3 ligand (Flt3L) knockout (KO)

114 Daily treatment of mice with fms-like tyrosine kinase 3 ligand (Flt3L) leads to a sig

115 Fms-like tyrosine kinase 3 ligand (Flt3L) mobilizes stem

116 Conversely, endogenous DC expansion using FMS-like tyrosine kinase 3 ligand (Flt3L) protected mice

117 In this study we demonstrate that Fms-like tyrosine kinase 3 ligand (Flt3L) recruits plasm

118 Fms-like tyrosine kinase 3 ligand (Flt3L) reverses the f

119 d deficiency (DCML deficiency) with elevated Fms-like tyrosine kinase 3 ligand (Flt3L) was observed i

120 ge inflammatory protein-1alpha (MIP-1alpha), fms-like tyrosine kinase 3 ligand (Flt3L), and the DNA v

121 Multiple subsets of FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent dend

122 ne liver pDCs, we expanded them in vivo with fms-like tyrosine kinase 3 ligand (Flt3L).

123 ministration of the potent DC growth factor, fms-like tyrosine kinase 3 ligand (Flt3L).

124 Mice lacking fms-like tyrosine kinase 3 ligand (Flt3L-/-) as the resu

125 rotein 3alpha (hCCL20/hMIP-3alpha), or human fms-like tyrosine kinase 3 ligand (hFlt3-L), factors pre

126 IP-1alpha) and the DC-specific growth factor fms-like tyrosine kinase 3 ligand with the DNA vaccine r

127 SCs in normal mice in response to SCF, IL-7, fms-like tyrosine kinase 3 ligand, and IL-15.

128 nes, including caveolin-1, semaphorin E, and FMS-like tyrosine kinase 3 ligand, have putative roles i

129 ter their stimulation with stem cell factor, Fms-like tyrosine kinase 3 ligand, interleukin-3, interl

130 DC progenitors and accumulate in response to Fms-like tyrosine kinase 3 ligand, yet appear divergent

131 lls were defective in generating pDCs in the fms-like tyrosine kinase 3 ligand-based culture system a

132 DC differentiation depends on IRF-4, whereas Fms-like tyrosine kinase 3 ligand-mediated differentiati

133 freshly isolated, immunobead-purified (>90%) fms-like tyrosine kinase 3 ligand-mobilized C57BL/10 (B1

134 DNA that encoded the secreted form of human fms-like tyrosine kinase 3 ligand.

135 The protein kinase fms-like tyrosine kinase 3 receptor (Flt3) has an import

136 ns leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blas

137 The ligand for the FMS-like tyrosine kinase 3 receptor (Flt3L) is necessary

138 ndritic cells (cDCs) requires the ligand for FMS-like tyrosine kinase 3 receptor (flt3L), but little

139 tion activating gene 1(+) lymphomyeloid, and Fms-like tyrosine kinase 3(+) fetal monocyte lineages.

140 ion with the receptor tyrosine kinases FLT3 (Fms-like tyrosine kinase 3) or KIT-induced ligand indepe

141 ations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in le

142 Recently, Flt3 (Fms-like tyrosine kinase 3)-ligand has been identified a

143 DC), the majority of which were derived from fms-like tyrosine kinase 3-dependent pre-DC, and CD11b(+

144 In FMS-like tyrosine kinase 3-internal tandem duplication (

145 FMS-like tyrosine kinase 3-internal tandem duplication (

146 enic tyrosine kinases, including BCR-ABL and FMS-like tyrosine kinase 3-internal tandem duplication (

147 f a juxtamembrane mutation in the FLT3 gene (FMS-like tyrosine kinase 3-internal tandem duplication [

148 Distinct expression patterns for FMS-like tyrosine kinase 3-internal tandem duplication w

149 Increases in fms-like tyrosine kinase-3 (FLT-3) ligand, reflecting FL

150 in or point mutation in the kinase domain of FMS-like tyrosine kinase-3 (FLT-3) mediates ligand-indep

151 yrosine kinase domain (TKD) mutations of the fms-like tyrosine kinase-3 (FLT3) gene in acute myeloid

152 We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtin

153 Fms-like tyrosine kinase-3 (FLT3) inhibitors have been u

154 Fms-like tyrosine kinase-3 (Flt3) ligand (FL) and Interl

155 viously demonstrated that pretreatments with fms-like tyrosine kinase-3 (Flt3) ligand (Flt3L), a dend

156 In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid l

157 al tandem duplication (ITD) mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor found in acut

158 Activating mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor occur in appr

159 andem duplication (ITD) mutations within the FMS-like tyrosine kinase-3 (FLT3) render the receptor co

160 FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibi

161 r of clinical trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibi

162 Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in

163 The clinical benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small molecul

164 FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplic

165 rbor a constitutively activating mutation in FMS-like tyrosine kinase-3 (FLT3).

166 cluding 14 (93%) of 15 patients with mutated FMS-like tyrosine kinase-3 (FLT3; the 15th patient had c

167 verexpression have been identified including FMS-like tyrosine kinase-3 and nucleophosmin, which will

168 Fms-like tyrosine kinase-3 ligand (Flt3L) is a hemopoiet

169 mon DC progenitor with conventional DCs, and Fms-like tyrosine kinase-3 ligand is essential for their

170 rsely, DC expansion induced either by Flt3L (fms-like tyrosine kinase-3 ligand) or adoptive transfer

171 kin-7, interleukin-15, stem cell factor, and fms-like tyrosine kinase-3 ligand).

172 endothelial cells were identified: endoglin, Fms-like tyrosine kinase-3 ligand, EGF-like repeats and

173 Internal tandem duplication of the Fms-like tyrosine kinase-3 receptor (FLT3) internal tand

174 ecreased in Mysm1(-/-) mice and defective in Fms-like tyrosine kinase-3(Flt3) ligand-induced, but not

175 l cell line-derived neurotrophic factor, and FMS-like tyrosine kinase-3.

176 e myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3).

177 ert domain-containing receptor (KDR) and the fms-like tyrosine kinase (Flt).

178 eraction with two receptor tyrosine kinases, fms-like tyrosine kinase (Flt-1) or VEGF receptor 1 and

179 ty for soluble kinase domain region (KDR) or Fms-like tyrosine kinase (FLT-1) receptors.

180 ain-containing receptor [KDR]), and VEGF-R1 (fms-like tyrosine kinase [Flt]) in bovine retinal endoth

181 Internal tandem duplication of the FMS-like tyrosine kinase (FLT3-ITD) receptor is present

182 ML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a targe

183 ated levels of hemopoietic cytokines such as fms-like tyrosine kinase ligand (FLT3-L, a dendritic cel

184 We tested the prediction that expression of fms-like tyrosine kinase ligand 3 (Flt3L) in the brain w

185 mpartment was associated with elevated serum fms-like tyrosine kinase ligand and reduced circulating

186 containing receptor, or VEGFR-2) and Flt-1 (fms-like tyrosine kinase, or VEGFR-1).

187 inding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracell

188 rosine kinase receptors, VEGF receptor 1 [or fms-like tyrosine kinase receptor (Flt-1)] and VEGF rece

189 PO), placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor (sFlt)-1, and galectin

190 mediated by soluble VEGF receptor 1/soluble Fms-like tyrosine kinase receptor 1 and soluble endoglin

191 We studied the effects of fms-like tyrosine kinase receptor 3 ligand (Flt3-L) or G

192 Fms-like tyrosine kinase receptor 3-ligand (Flt3-L) and

193 tion of specific DC subsets-using GM-CSF and fms-like tyrosine kinase receptor 3-ligand (Flt3-L)-on t

194 ie2 (sTie2) and VEGF signalling with soluble Fms-like tyrosine kinase receptor-1 (sFlt1).

195 levels of brain natriuretic factor, soluble fms-like tyrosine kinase receptor-1, troponin I, and cre

196 oxidase, B-type natriuretic peptide, soluble fms-like tyrosine kinase receptor-1, troponin I, soluble

197 ically linked to the extracellular domain of Fms-like tyrosine kinase receptor-3 ligand (FLex; a DC g

198 We conclude that fms-like tyrosine kinase receptor-3 signaling is require

199 ethymic signal through the cytokine receptor fms-like tyrosine kinase receptor-3 was required for the

200 controlled in part by regulatory T cells and fms-like tyrosine kinase receptor-3.

201 asma angiogenic factor expression of soluble fms-like tyrosine kinase (sFlt)-1.